NuWays keeps NanoRepro at Buy, sets EUR 4.4 price target

• NuWays reiterated a BUY on NanoRepro with a 12-month target price of EUR 4.4.
• Report flagged the acquisition of the remaining 67% of hyped about science, bringing the ALPHABIOL nutritional elixirs brand fully in-house.
• Deal terms included EUR 25,000 cash consideration, transfer of the Phlas brand to terraplasma, and EUR 1 million of capital held in the acquired entity.
• NuWays forecasts FY26 sales of EUR 19 million, up 18.7% year-on-year, with EBITDA improving to EUR -0.3 million from EUR -1.7 million.
• Analyst expects three core pillars, with EBITDA margin projected to reach 5% in FY27 from -11% in FY25.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoRepro AG published the original content used to generate this news brief via EQS News (Ref. ID: rc_26728) on September 03, 2026, and is solely responsible for the information contained therein.